Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis
Elayi C, Shohoudi A, Moodie E, Etaee F, Guglin M, Roy D, Khairy P, Investigators A. Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. International Journal Of Cardiology 2020, 313: 48-54. PMID: 32320783, DOI: 10.1016/j.ijcard.2020.04.047.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Arrhythmia AgentsAtrial FibrillationDigoxinHeart FailureHospitalizationHumansStroke VolumeConceptsReduced ejection fractionAtrial fibrillationCardiovascular hospitalizationEjection fractionImpact of digoxinArrhythmic deathHazard ratioHeart failureCongestive Heart Failure trialAF-CHF trialsHeart Failure TrialSafety of digoxinSubgroup of patientsMarginal structural modelingCardiovascular causesCause mortalityCardiac hospitalizationSecondary outcomesFailure TrialClinical benefitHospitalizationPatientsDigoxinFibrillationOne-year